amodiaquine-artesunate versus amodiaquine — Competitive Intelligence Brief

amodiaquine-artesunate versus amodiaquine (amodiaquine-artesunate versus amodiaquine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

marketed Antimalarial combination Malaria parasite heme detoxification pathway; artemisinin-derived endoperoxide bridge Infectious Disease Small molecule

Target snapshot

amodiaquine-artesunate versus amodiaquine (amodiaquine-artesunate versus amodiaquine) — Charite University, Berlin, Germany. Amodiaquine-artesunate is a fixed-dose combination antimalarial that combines a quinoline derivative with a fast-acting artemisinin to kill malaria parasites through multiple mechanisms.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
amodiaquine-artesunate versus amodiaquine TARGET	amodiaquine-artesunate versus amodiaquine	Charite University, Berlin, Germany	marketed	Antimalarial combination	Malaria parasite heme detoxification pathway; artemisinin-derived endoperoxide bridge
Artemether-lumefantrine combination plus albendazole	Artemether-lumefantrine combination plus albendazole	Navrongo Health Research Centre, Ghana	marketed	Antimalarial combination with anthelmintic	Plasmodium falciparum (multiple mechanisms); Ascaris, Hookworm, Trichuris (tubulin)
IPTp-SP	IPTp-SP	Kenya Medical Research Institute	marketed	Antifolate antimalarial combination	Dihydrofolate reductase (DHFR)
Artesunate plus Amodiaquine	Artesunate plus Amodiaquine	Bernhard Nocht Institute for Tropical Medicine	marketed	Antimalarial combination therapy	Plasmodium falciparum (multiple parasite targets including heme detoxification pathway and DNA synthesis)
Coadministered Artesunate plus Amodiaquine	Coadministered Artesunate plus Amodiaquine	Professor Anders Björkman	marketed	Antimalarial combination therapy	Plasmodium falciparum heme metabolism and protein synthesis
Quinine plus sulfadoxine-pyrimethamine	Quinine plus sulfadoxine-pyrimethamine	Albert Schweitzer Hospital	marketed	Antimalarial combination	Plasmodium DNA/protein synthesis; dihydrofolate reductase; dihydropteroate synthase
Sulfadoxine-pyrimethamine plus artesunate	Sulfadoxine-pyrimethamine plus artesunate	London School of Hygiene and Tropical Medicine	marketed	Antimalarial combination	Dihydrofolate reductase, dihydropteroate synthase (sulfadoxine-pyrimethamine); mitochondrial electron transport (artesunate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class